1 / 34

B-type Natriuretic Peptide (BNP) in the Diagnosis of Acute Congestive Heart Failure (CHF)

B-type Natriuretic Peptide (BNP) in the Diagnosis of Acute Congestive Heart Failure (CHF). Scott M Silvers, MD 1 st Annual Pan American Conference Emergency Medicine Clinical Policies November 6 – 7, 2003. Lecture Outline. Introduction to BNP Case Critical Question Literature Search

wright
Télécharger la présentation

B-type Natriuretic Peptide (BNP) in the Diagnosis of Acute Congestive Heart Failure (CHF)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. B-type Natriuretic Peptide(BNP) in the Diagnosis of Acute Congestive Heart Failure (CHF) Scott M Silvers, MD 1st Annual Pan American Conference Emergency Medicine Clinical Policies November 6 – 7, 2003

  2. Lecture Outline • Introduction to BNP • Case • Critical Question • Literature Search • Critical Literature Evaluation • Evidence-based Recommendations

  3. 32-aa polypeptide Found in heart ventricles Produced with  ventricular stretch and volume Results in vasodilation, natriuresis, diuresis, and reduced preload Increases with worsening heart failure Introduction to BNP

  4. Introduction to BNP Maisel AS, et al. N Engl J Med. 2002;347(3):161-167.

  5. Introduction to BNP Morrison LK, et al. J American Coll of Card. 2002;39(2):202-209.

  6. Case Current History: Ms. GM is a 76 yo woman with a history only of obstructive lung disease who presents to the emergency department with 2 days of progressively worsening shortness of breath. Physical Examination T= 37°C HR= 110 BP= 170/90 RR= 40 SO2 (air)= 87% She is unable to speak long sentences. Neck veins: difficult to assess Heart: difficult to hear over her lung sounds Lungs: diffuse wheezing with decreased breath sounds and rales at the bases Abdomen: normal Extremities: warm with moderate pitting edema

  7. Chest X-ray

  8. Critical Question What is the utility of a B-type natriuretic peptide (BNP) measurement in the diagnosis of congestive heart failure among patients presenting to an emergency department with shortness of breath?

  9. Curiosity Poll How many people have a BNP assay available to them where they practice?

  10. Literature Search • Medline January 1995 – Present • Keywords • “Brain natriuretic peptide”, “B-type natriuretic peptide,” “B natriuretic peptide,” or “BNP” • 1, 745 papers • Limits • Human subjects, clinical trials, meta-analyses • 164 papers

  11. Literature Search • Abstracts of clinical studies reviewed • Patients presenting with shortness of breath to “acute care” centers • 5 papers • Reviews and clinical policies 2000 - present (references crosschecked)

  12. Typical Study Methodology Inclusion Criteria • Adult patients presenting to an “acute care” facility • Primary complaint shortness of breath Exclusion Criteria • Obvious non-CHF cause of shortness of breath • Renal Failure • Acute myocardial infarction

  13. Typical Study Methodology • Evaluation by an emergency physician • Assessment of clinical probability of CHF • BNP assay sent • Results not revealed to emergency physician • Patient treated and dispositioned • Physician team blinded to BNP measurement assign final diagnosis after evaluation of case

  14. Typical Study Methodology CHF “Gold Standard” • Clinical findings • Chest x-ray • Echocardiography • Nuclear cardiology • Cardiac Catheterization • Framingham and NHANES scores • Clinical response to therapies

  15. Critical Literature Evaluation:BNP in Diagnosing CHF • 5 published studies to date • 2 report data from the same sample

  16. Critical Literature Evaluation:BNP in Diagnosing CHF

  17. Critical Literature Evaluation:BNP in Diagnosing CHF Maisel et al, (NEJM 2002) • Prospective, multinational; N = 1,586 • All “clinical risk” patients evaluated as one sample • BNP < 22 pmol/L (100 pg/ml) for detecting CHF Sensitivity = 90% Specificity = 76% NPV = 89% PPV = 79% • BNP < 11 pmol/L (50 pg/ml) for detecting CHF Sensitivity = 97% Specificity = 62% NPV = 96% PPV = 71% • Study Grade = 1

  18. Critical Literature Evaluation:BNP in Diagnosing CHF McCullough et al, (Circulation 2002) • Prospective, multinational; N = 1,538 • Excluded 48 patients without “clinical risk” assessement • BNP < 22 pmol/L (100 pg/ml) • “Low and Intermediate” clinical probability (0 – 79%) Sensitivity = 94% Specificity = 70% NPV = 93% PPV = 74% • “High” clinical probability (80 – 100%) Sensitivity = 49% Specificity = 96% NPV = 68% PPV = 91% • Study Grade = 2 (Post-study Analysis)

  19. Critical Literature Evaluation

  20. Critical Literature Evaluation

  21. Critical Literature Evaluation

  22. Critical Literature Evaluation Maisel AS, et al. N Engl J Med. 2002;347(3):161-167.

  23. Critical Literature Evaluation • Possible Limitation of BNP • Among rats given acute CHF, BNP may take over 1 hour to rise. Nakagawa O, et al. J Clin Invest. 1995;96:1280-1287.

  24. Evidenced-based Recommendations Includes • Patients presenting to an emergency department • Primary complaint shortness of breath Excludes • Obvious non-CHF cause of shortness of breath • Renal Failure • Acute myocardial infarction

  25. Evidenced-based Recommendations Level A Recommendations • A BNP < 11 pmol/L (50 pg/ml) may be used to help rule-out the diagnosis of congestive heart failure when the diagnosis is uncertain. (Probability < 4%).

  26. Evidenced-based Recommendations Level B Recommedations • Among low and intermediate “clinical probability” patients, a BNP < 22 pmol/L (100 pg/ml) may be used to help rule-out the diagnosis of congestive heart failure. (Probability < 5%) • Among patients without a history of CHF, a BNP > 88 pmol/L (400 pg/ml) may be used to rule-in the diagnosis of CHF when the diagnosis is uncertain. (Probability > 95%) • A BNP > 220 pmol/L (1,000 pg/ml) may be used to rule-in the diagnosis of acute CHF among patients presenting with a history of CHF. (Probability > 95%)

  27. Evidenced-based Recommendations Level C Recommendations • When evaluating a patient who presents with possible CHF within 1 hour from symptom onset, use caution in the interpretation of a low BNP level as BNP may take over 1 hour to rise.

  28. Key References • Davis M, et al. Plasma brain natriuretic peptide in assessment of acute dyspnea. Lancet. 1994;343:440-444. • Dao Q, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Amer Coll Card. 2001;37(2):379-385. • Morrison LK, et al. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Amer Coll Card. 2002;39(2):202-209. • Maisel AS, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. New Eng J Med. 2002;347(3):161-167. • McCullough PA, et al. B-typenatriuretic peptide and clinical judgement in emergency diagnosis of heart failure – Analysis from breathing not properly (BNP) multinational study. Circulation. 2002;106:416-422. • Nakagawa O, et al. Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. J Clin Invest. 1995;96:1280-1287.

  29. The End

More Related